The Hong Kong market has witnessed notable activity recently, with the Hang Seng Index rising against the backdrop of cautious global sentiment and a loose economic calendar. This environment provides the basis for examining high-growth technology stocks that could potentially thrive in these conditions. In this article, we will examine three promising technology stocks in Hong Kong and focus on their potential to benefit from the current market dynamics and economic indicators.

The 10 fastest growing technology companies in Hong Kong

Click here to see the full list of 48 stocks from our SEHK High Growth Tech & AI Stocks Screener.

We examine a selection of our screener results.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kuaishou Technology, an investment holding company, provides live streaming, online marketing and other services in the People’s Republic of China with a market capitalization of HK$176.76 billion.

Operations: Kuaishou Technology generates its revenue mainly from domestic business, totaling CN¥117.32 billion, with a smaller contribution of CN¥3.57 billion from overseas. The company’s business model includes live streaming and online marketing services in China.

Kuaishou Technology’s latest earnings report shows a clear growth curve. In the second quarter of 2024, revenue reached 30.98 billion yen (up from 27.74 billion yen a year earlier) and net profit increased from 1.48 billion yen to 3.98 billion yen. The company’s innovative Kling AI model has been significantly upgraded, improving video quality and user engagement through new subscription tiers priced between 66 and 666 RMB per month. Research and development spending is central to their strategy. Last year alone, 19.9% ​​of revenue was spent on research and development initiatives, underscoring their commitment to technological advancement.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Shanghai Henlius Biotech, Inc. is engaged in the research and development of biological drugs with a focus on oncology, autoimmune diseases and ophthalmic diseases and has a market capitalization of HK$12.45 billion.

Operations: The company generates its revenue mainly in the pharmaceutical segment, which reported 5.39 billion CNY. The main areas of focus are oncology, autoimmune diseases and eye diseases.

Shanghai Henlius Biotech’s recent financial performance underscores its growth potential in the biotech sector. Half-year revenue reached 2.75 billion yen (up from 2.50 billion yen last year) and net profit increased from 240 million yen to 386.3 million yen. The company has invested 15.8% of its revenue in research and development, driving advances such as the HLX53 clinical trial for the treatment of hepatocellular carcinoma. With forecast profit growth of 15.77% per year and a clear focus on innovative therapies such as HANSIZHUANG, Henlius is positioning itself strongly in the competitive landscape of biotech innovation in Hong Kong.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lenovo Group Limited, an investment holding company with a market capitalization of HK$116.98 billion, develops, manufactures and markets technology products and services.

Operations: Lenovo Group Limited generates revenues in three main segments: Intelligent Devices Group (IDG) of US$45.76 billion, Solutions and Services Group (SSG) of US$7.64 billion, and Infrastructure Solutions Group (ISG) of US$10.17 billion. The company focuses on developing, manufacturing, and marketing a broad range of technology products and services.

Lenovo Group’s Q1 2024 results show a robust performance with revenue of $15.45 billion (compared to $12.90 billion last year) and net profit up from $176.53 million to $243.37 million. The company allocated 7.9% of its revenue to R&D expenses, focusing on innovations such as the AD1 autonomous driving domain controller, which boasts an impressive 2100 TOPS@FP8/INT8 computing power. In addition, annual profit growth of 18.6% is forecast for the next few years, outperforming the Hong Kong market’s average growth rate of 10.9%.

Take advantage of the opportunity

Looking for a new perspective?

This Simply Wall St article is of a general nature. We comment solely on historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.

Do you have feedback on this article? Are you interested in the content? Contact us directly. Alternatively, send an email to [email protected]